951777-95-0

Upstream product

• 951777-94-9 (S)-2-[(1'S,3a'R,4'S,7a'R)-4'-hydroxy-7a'-methyl-octahydro-inden-1'-yl]-2-methylbutyraldehyde 
• 1576-35-8 toluene-4-sulfonic acid hydrazide 
• 1006877-89-9 benzoic acid (1R,3aR,4S,7aR)-1-[(S)-(2'-hydroxyimino-1'-methyl)ethyl]-7a-methyl-octahydro-inden-4-yl ester 
• 951777-93-8 (S)-2-[(1'S,3a'R,4'S,7a'R)-4'-hydroxy-7a'-methyl-octahydro-inden-1'-yl]-2-methylbutylnitrile 
• 951777-92-7 benzoic acid (1S,3aR,4S,7aR)-1-[(S)-1'-cyano-1'-methylpropyl]-7a-methyl-octahydro-inden-4-yl ester 
• 951777-91-6 benzoic acid (1R,3aR,4S,7aR)-1-[(S)-1'-cyano-ethyl]-7a-methyl-octahydro-inden-4-yl ester 

Relevant academic research and scientific papers

Synthesis and biological activity of 2-(3′-hydroxypropylidene)- 1α-hydroxy-19-norvitamin D analogues with shortened alkyl side chains

As a continuation of our efforts directed to vitamin D compounds of promising biological properties, 19-norvitamins 9-13, possessing a 3′-hydroxypropylidene fragment attached to C-2 and shortened 17β-alkyl chains, were synthesized. A new synthetic pathway

2-Methylene-20-Methyl-19,24,25,26,27-Pentanor-Vitamin D Analogs

This invention discloses 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin D analogs, and specifically 2-methylene-20-methyl-1α-hydroxy-19,24,25,26,27-pentanor-vitamin D3, and pharmaceutical uses therefore. This compound exhibits activity i

1alpha-Hydroxy-2-(3'-Hydroxypropylidene)-19-Nor-Vitamin D Compounds with a 1,1-Dimethylpropyl Side Chain

This invention discloses 1α-hydroxy-2-(3′-hydroxypropylidene)-19-nor-vitamin D compounds with a 1,1-dimethylpropyl side chain, and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated